Clinical Trial · NCT07657494

Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study

Overview

This multicenter study aims to evaluate the predictive value of tumor microenvironment PET/CT imaging for treatment response and prognosis in patients with aggressive lymphoma. Eligible patients with histologically confirmed aggressive lymphoma will undergo FAPI PET/CT imaging, and selected patients who are candidates for immunotherapy will undergo Grazytracer PET/CT imaging. These imaging methods are intended to assess fibroblast activation protein expression and granzyme B activity in lymphoma lesions, reflecting cancer-associated fibroblasts and cytotoxic T-cell activity in the tumor microenvironment. The study will explore optimal imaging assessment criteria and develop clinical-pathological-imaging models to predict treatment response, prognosis, and the relationship between tumor heterogeneity and refractory or relapsed disease.

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase

N/A

Contacts

Xuejuan Wang, M.D. (STUDY_CHAIR)

Xin Liu, M.D. (CONTACT)

liux0077@163.com

15621479631

ClinicalTrials.gov

NCT07657494

Drug / Compound

NOTA-FAPI

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Chelator: NOTA

NOTA-grazytracer

Isotope(s):

Target(s):

Granzyme B

Ligand Class: Small Molecules

Chelator: NOTA

Eligibility

Inclusion

Expected survival of at least 6 months and ability to complete follow-up.
* Histologically confirmed aggressive lymphoma.
No significant cardiac, hepatic, or renal dysfunction.
No previous history of malignant tumors.
Baseline PET/CT showing moderate to high FDG uptake in lymphoma lesions.

Exclusion

Active or uncontrolled chronic inflammation or infection.
Uncontrolled diabetes mellitus.
Lymphoma lesions have been surgically removed, with no positive lesions available for evaluation.
Incomplete clinical data or loss to follow-up.
* Low FDG uptake on baseline PET/CT.